BRILINTA in combination with aspirin could be the first FDA-approved dual antiplatelet therapy to reduce the rate of stroke in these high-risk patients WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...
British drugmaker AstraZeneca has placed a lot of faith—and money—in its wide-ranging R&D program for aging blood thinner Brilinta in hopes of major label expansions. So far, those results have been ...
Credit: Getty Images. The FDA has granted Priority Review of the supplemental New Drug Application for Brilinta (ticagrelor; AstraZeneca), for use in combination with aspirin, to reduce the rate of ...
(RTTNews) - AstraZeneca (AZN.L, AZN) announced Thursday the US Food and Drug Administration has accepted a supplemental New Drug Application or sNDA and granted Priority Review for Brilinta ...
AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of ...
Brilinta (ticagrelor) is a brand-name drug that’s prescribed to help lower the risk of blood clots or certain cardiovascular events, such as heart attack or stroke in adults. As with other drugs, ...
BRILINTA indicated to reduce heart attacks and cardiovascular death in patients with Acute Coronary Syndrome WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) announced today that the US ...
WILMINGTON, Del.-- (BUSINESS WIRE)--AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback